Imunon, Inc. · NASDAQ:IMNN
Imunon — Investor Presentation (November 2022)
32 slides from Imunon's investor presentation, Nov 15, 2022
Slide 1: Corporate Presentation
IMUNON Corporate Presentation November 2022 Nasdaq: IMNN SIMUNON | © 2022 IMUNON Inc. pace | 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and any statements made during any presentation or meeting contain forward-looking statements related to Imunon, Inc. (“Imunon”) under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks an
Slide 3: Leveraging innovative plasmid DNA platform with proprietary synthetic delivery systems
Leveraging innovative plasmid DNA platform with proprietary synthetic delivery systems and multiple potential indications * Initial clinical fous is on immuno-oncology and infectious diseases Developing new medicines that * Development of the PLACCINE modality in prophylactic vaccines, with strong e
Slide 4: Experienced Management Team
Experienced Management Team Corinne Le Goff, PharmD MBA President, CEO and Nicholas Borys, MD Executive Vice President and SIMUNON | ©2022 IMUNON Ine Khursheed Anwer, PhD MBA Executive Vice President Jeffrey W. Church Anthony Recupero, PhD Executive Vie President, CFO Vice President Director Chief M
Slide 5: Vaccine Modality: PLACCINE
Vaccine Modality: PLACCINE * DNA Plasmid vectors engineered for next generation vaccine technology * Designed for multiple antigens/epitopes with co-expression of immunomodulators Self-assembling Synthetic Nanocarriers SARS-CoV-2 Multivalent Vaccine for COVID-19 Preclinical Development Stage SIMUNON
Slide 6: IMUNON's Pipeline of DNA-based Transformative Medicines
IMUNON’s Pipeline of DNA-based Transformative Medicines Platform Indication(s) Discovery IND enabling | Phase 1 | Phase2 | IL-12 (OVATION) Advanced Ovarian, Intraperitoneal (IP) Fallopian Tube or Primary GEN-1 Peritoneal Cancer \ TheraPlas . with bevacizumab SAR, feces ENP Peritoneal Cancer Mukticis
Slide 7: PLACCINE SARS-CoV-2 Proof of Concept
PLACCINE sars-cov-2 PROOF OF CONCEPT PROPHYLACTIC VACCINES PROGRAM “SIMUNON | ©2022 IMUNON Inc. aeee 7
Slide 8: More than Pathogenic Viruses Discovered since 1980
More than 80 Pathogenic Viruses Discovered since 1980 Less than 4% have a vaccine commercially available Novel Viruses Discovered 10 4 (1980-2019) 9 4 3 84 2 37 a Be 25 ° 4 33 22 > * 1 oJ Fi) 1980 1985 1990 1995 2000 2005 2010 20152019 Sferow fover(I90}) > tka (1952) + Hepatiiss (1965) Year of First
Slide 9: PLACCINE Platform: Powering the Next Generation of Vaccines
PLACCINE Platform: Powering the Next Generation of Vaccines By addressing the shortcomings of current nucleic acid, viral vector and protein subunit vaccines Muklticistronic pDNA Synthetic Nanoparticles Administration Expression Vector Delivery Systems Complexes A Intradermal Ss Intramuscular & Intr
Slide 10: Multicistronic vector: pVac-17
Multicistronic vector: pVac-17 D614G, Delta PLACCINE * Spike antigen: * Formulation: * 125 jg DNA * IgG & nAB titer (day 35) Bivalent PLACCINE Vaccine Produces Stronger Neutralizing Immune Response than mRNA Benchmark ng Antibody Titer (pseudovirus competition assay) Delta Variant Ic50 Titer 4 ——> D
Slide 11: Over 90% Protection From Live Viral Challenge
10" 108 10°. TCIDso/gm of lung 108 40°. <p, | Over 90% Protection From Live Viral Challenge Activity of PLACCINE-SARS-CoV-2 Vaccines in hACE2:K18 SARS-CoV-2 Model pVac-15- D614G pVac-16- Delta pVac-17- D614G - Delta Formulation: PLACCINE Dose- 125 1g DNA 0 13:14 35 42 bid TCID5O Tissue Culture Infec
Slide 12: Monovalent PLACCINE Vaccine is Immunogenic in Cynomolgus Monkeys
2 Monovalent PLACCINE Vaccine is Immunogenic in Cynomolgus Monkeys PLACCINE Subjects Showed IgG and neutralizing Antibody Response * Single antigen vecor pVae-15 (D614G) in PLACCINE * Comparator mRNA Commercial mRNA Vaccine (INP) © Dosing schedule Day 1, 28,84 + IgG titer Day 105 (21 days after 3 do
Slide 13: Viral Clearance by PLACCINE is Comparable to mRNA Vaccine
Viral Clearance by PLACCINE is Comparable to mRNA Vaccine Clearance efficiency comparable to mRNA vaccine by PCR assay : >99% clearance 10°. Nasal Swab as Bronchoalveolar Lavage ‘oe . ie . wo" = =e 10% : a = ati “* ~~ = Plasebo obug a0 Placebo 100ug mg mRNA PLACCINE mRNA. PLACCINE pVac-15 iar . pVac
Slide 14: pDNA Yields More Durable Antigen Expression
pDNA Yields More Durable Antigen Expression than the Protein or modified MRNA VEGFA protein (ng/ml) 72 Time (h) Chien KR Cold Spring Harb Perspect Med 2015;5:a014035 120 144 SIMUNON | © 2022 IMUNON Inc. Average Radiance [pisicm*/st] 108 107. 108 10° 104 108 102. Day 1 Day3 Day7 Day 14 Day 21 Day 28
Slide 15: Durable Neutralizing Antibody Response to PLACCINE-SARS-CoV-2 Vaccines
Durable Neutralizing Antibody Response to PLACCINE-SARS-CoV-2 Vaccines Evidence of Durability For 8 Months (Ongoing Study) © Vectors: pVac-16 (Delta), pVac-17 (D614G -Delta) * 125 [tg DNA * IgG titer (2, 3, 5 months) nAB Assessment by a Delta Pseudo Lentivirus Assay @ 1 Month @ 2Montns @ 3Months @ 5
Slide 16: PLACCINE is Stable at 4°C for Six Months or Longer
Ss PLACCINE is Stable at 4°C for Six Months or Longer Vector: pVac-17 (D614G-Delta) Formulation: PLACCINE PLACCINE e 4 4°C Storage 1 3 6 9 12 Immunogenicity Studies in Mice Months IMUNON | © 2022 IMUNON tne. Endpoint Titer 408. sot. agen Fresh 4c PAGE 16
Slide 17: GEN-1 IL-12 Immuno-Oncology Program
GEN-1 IL-12 IMMUNO-ONCOLOGY PROGRAM SIMUNON | ©2022 IMUNON Inc.
Slide 18: IL-12: A Powerful Immune-Modulating Agent
IL-12: A Powerful Immune-Modulating Agent Interleukin- 12 Can Induce Anti-cancer Immunity Through Multiple Mechanisms Stimulates the proliferation of CD-8 positive T-cells and natural Activation/Proliferation killer (NK) cells and their cytotoxic activity against the tumor Shifts the differentiation
Slide 19: First Target: Ovarian Cancer
First Target: Ovarian Cancer 20,000 cases diagnosed each year in U.S. Standard of care has remained 13,000 deaths stagnant for decades diagnosed in late stage (III/IV) 225,000 si 50% cases per year Globally lead ¢ ali will die within 5 years of diagnosis > 100,000 esa aa vonen oo“ Patients in the U.
Slide 20: Survival Benefit of GEN-1 in an ID-8 Mouse Ovarian Cancer Model
<2» | Survival Benefit of GEN-1 in an ID-8 Mouse Ovarian Cancer Model Dose dependent effects of intraperitoneal mGEN- 1: * Reduction in tumor ascites * Reduction in tumor weight Median Survival CO Contro! I Paclitaxel/Carboplatin i | mGEN-1 HB GEN-1 + Paclitaxel/Carboplatin + Improvement in survival
Slide 21: GEN-1 Targets the Micro-Environment of Ovarian Cancer
GEN-1 Targets the Micro-Environment of Ovarian Cancer Local production of safe and durable levels of a powerful anti-cancer immune agent, IL- 12 Intracavity infusion of GEN-1 has demonstrated durable and local expression of IL-12 in the peritoneum No supraphysiological increases in IL-12 commonly as
Slide 22: GEN-1 has the potential to play a key role in new combination strategies
As an Immuno-oncology Agent, GEN-1 has the potential to playa key role in new combination strategies tages Il tolV il Debulking surgery NACT in frail patients w /extensive disease Induction therapy (1L) | Interval ey Surgery (IDS) Platinum-Taxanes chemotherapy +/- bevacizunab, +/- PARPi BRCA + or HR
Slide 23: GEN-1 OVATION Ovarian Cancer Study
GEN-1 OVATION 2 Ovarian Cancer Study To Determine Efficacy and Biological Activity With NAC in Stage III/IV Patients <—l] fe] fae (SF ray ol Amt |) é evans” | a ¥ il Adjuvant Chemotherapy Newly Diagnosed Neoadjuvant Chemotherapy (NACT) Interval Debulking : Ovarian Cancer + Surgery (olntenence Therap
Slide 24: Interim OVATION Data suggest that GEN-1 is Safe and Active
Interim OVATION 2 Data suggest that GEN-1 is Safe and Active ITT population: PFS benefit likely confounded by PARPi positive impact (50% of events) Celsion Study 201-17-201: Analysis of Progression Free Survival Time (Cutoff Date: 06SEP2022) Kaplan-Meier Survival Plot and Log-rank Test All subjects
Slide 25: Interim OVATION Data Indicates Subjects on GEN-1 who are BRCA-/HRP May Have Improved PFS
Interim OVATION 2 Data Indicates Subjects on GEN-1 who are BRCA-/HRP May Have Improved PFS Sub-population of patients with the greatest medical need Targeted Therapy Approach HRP (homologous recombination proficient with no BRCA 1/2 mutations) * Early data suggests 3-month improvement in this identi
Slide 26: Synergistic Antiangiogenic Effect of GEN-1 with Avastin in Ovarian Cancer
<2s |Synergistic Antiangiogenic Effect of GEN-1 with Avastin in Ovarian Cancer SKOV-3 Ovarian Cancer in Nude Mice Key Rationale for Combination of GEN-1 with Avastin® 90 ~ Hh controt Bi vcen ° Synergistic efficacy potential ° Bil A asin (low/mee/tigh) of VEGF level reduction by se EBB GEN-1 + Avasti
Slide 27: New Phase Study in Combination with bevacizumab
New Phase 2 Study in Combination with bevacizumab Avastin (BEV) + GEN-1 Study Design in Advanced Epithelial Ovarian Cancer. Accepted by the FDA. IDS SLL Maintenance N=50 from 4 sites Pac/Carbo x 4-6 Pac/Carbo x 3 BEV BEV x2 BEV x 2 PARPi(HRD only) Neoadjuvant Chemotherapy —> NACT 1 Pac/Carbo x 4-6 P
Slide 28: Summary of Development Programs
Summary of Development Programs GEN-1 offers a novel way to harness the PLACCINE SARS-CoV-2 Proof Concept has powerful immunological properties of demonstrated that our multicistronic IL-1 2: the “Master Switch” to the body’s formulated plasmid DNA platform can immune system. produce a robust immune
Slide 29: Milestones & Financials
Milestones & Financials SSIMUNON | © 2022 IMUNON Inc.
Slide 30: Upcoming Key Milestones
Ss; Upcoming Key Milestones: Robust Flowof Value Creating Activities Initiation of GEN-1 P2 Combo trial with bevacizumab GEN-1 OVATION 2 ORR & Surgical Data PLACCINE NHP SARS-Cov2 Data SARS-Cov2 Booster IND PLACCINE Next Pathogen Target GEN-1 OVATION 2 Interim Data PL-X Pre-clinical Challenge Data P
Slide 31: Strong Balance Sheet Supports Upcoming Milestones
Strong Balance Sheet Supports Upcoming Milestones Cash Runway into 2025 Common shares outstanding Cash + Investments @ 9/30/2022 $43.4 million @ 9/30/2022 7.1 million + Stock Options 0.9 million Projected NOL sales — 2022-2024 + $3.5 million Garena 0.2 million Total $46.9 million Fully diluted share
Slide 32: Corporate Information
Corporate Information Research Faci Huntsville, AL Headquarters Princeton, NJ IMUNON 997 Lenox Drive, Suite 100 P 609-896-9100 Ww imunon.com Lawrenceville, NJ 08648 F 609-896-2200 Nasdaq: IMNN SIMUNON | ©2022 IMUNON tn. pace | 32